Vijay Subramaniam
Pulmonary Disease · Williamsburg, VANPI 1962510370
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $162,003 of the $227,740 with a category attached, or 71.1%. United Therapeutics Corporation accounts for 69.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $157,237 and has fallen 99.9% since, to $80 in 2023. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $1650.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$157K
- GSK$63K
- Boehringer Ingelheim$6K
- Shionogi Inc$448
- Grifols USA, LLC$264
- AstraZeneca$233
- plus $484 from 13 others
Across 291 payments — averaging $3545.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covis Pharma GmbH$350K
- Merck$182K
- GSK$146K
- AstraZeneca$111K
- Shionogi Inc$88K
- Astrazeneca AB$81K
- plus $75K from 2 others
What the payments were for
- Consulting fees$162,00371%
- Speaking & faculty fees$60,49027%
- Travel & lodging$3,1251%
- Food & beverage$2,0061%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 23 | $157,409 |
| GSK | 54 | $63,036 |
| Boehringer Ingelheim | 14 | $5,866 |
| Shionogi Inc | 6 | $448 |
| Grifols USA, LLC | 10 | $264 |
| AstraZeneca(2 entities) | 11 | $233 |
| Amgen | 4 | $91 |
| Actelion Pharmaceuticals US, Inc. | 1 | $80 |
| Pulmonx Corporation | 2 | $79 |
| Resmed Corp | 2 | $43 |
| Novartis | 2 | $39 |
| Mylan Specialty L.p. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| UCB, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$58,659
- OFEV$5,558
- ANORO$3,600
- TYVASO$923
How this compares
$227,740 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Williamsburg
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
- Neil SheaArlington$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.